摘要
目的对肿瘤标志物免疫测定的标准化在肿瘤疾病诊断中的价值作用进行研究。方法选取我院2014年1月至2018年12月收治的28例乳腺癌患者,作为观察组;同时选取我院同期收治的28例乳腺良性肿块疾病患者,作为对照组,所选取患者的疾病情况均经病理学检查确认。临床中,采用化学发光免疫检测技术对两组患者的肿瘤标志物进行检测分析,并对其检测结果进行对比,以对肿瘤标志物免疫测定的标准化在肿瘤疾病诊断中的价值作用进行判断。结果对比显示,观察组患者CEA、CA15-3检测结果分别为(28.1±15.2)ng/mL和(49.8±23.6)U/mL,对照组分别为(7.8±4.6)ng/mL和(11.1±7.6)U/mL,两组对比差异显著,t=12.497、24.082,P<0.05,具有统计学意义。此外,对28例经病理学检查确认为乳腺癌的患者,采用化学发光免疫检测技术进行诊断显示,其符合率为26/92.9%,效果较为显著。结论采用标准的肿瘤标志物免疫测定分析进行患者肿瘤疾病诊断准确性较高,值得临床推广应用。
Objective to study value and effect of immunoassay standardization of tumor markers in diagnosis of tumor diseases.Methods choose 28 cases breast cancer patients admitted to our hospital from January 2014 to December 2018 as observation group,and 28 cases benign breast mass disease patients in our hospital at the same time as control group.Disease conditions of patients were confirmed by pathological examination.In clinical practice,detect and analyze tumor markers of two groups with chemiluminescent immunoassay.Compare detection results,and analyze value and effect of immunoassay standardization of tumor markers in diagnosis of tumor diseases.Results comparison showed,detection results of CEA and CA15-3 were(28.1±15.2)ng/ml and(49.8±23.6)U/ml in observation group,and(7.8±4.6)ng/ml and(11.1±7.6)U/ml in control group respectively.Difference between two groups was statistically significant(t=12.497 and 24.082,P<0.05).In addition,chemiluminescent immunoassay diagnosis of 28 cases breast cancer confirmed with pathological examination showed,coincidence rate was 26/92.9%,with significant effect.Conclusion immunoassay standardization of tumor markers has high accuracy in diagnosis of tumor diseases,which is worthy of clinical promotion and application.
作者
郑公海
ZHENG Gong-hai(Laboratory Department,Jianyang City Jiajia Central Hospital,Chengdu,Sichuan 641421)
出处
《智慧健康》
2020年第3期54-55,共2页
Smart Healthcare
关键词
肿瘤标志物
免疫测定
标准化
诊断
价值作用
Tumor marker
Immunoassay
Standardization
Diagnossis
Value effect
